Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year High – What’s Next?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $2.46 and last traded at $2.4150, with a volume of 444143 shares traded. The stock had previously closed at $2.29.

Analyst Ratings Changes

Several research firms have recently weighed in on AUTL. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Weiss Ratings raised shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Stock Down 3.1%

The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The business’s fifty day moving average price is $1.71 and its two-hundred day moving average price is $1.60. The firm has a market cap of $654.76 million, a P/E ratio of -2.32 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The firm had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. As a group, equities research analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.75 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics during the second quarter worth approximately $26,625,152,000. Alphabet Inc. bought a new position in shares of Autolus Therapeutics in the second quarter valued at approximately $1,117,000. Armistice Capital LLC lifted its stake in shares of Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after buying an additional 1,900,000 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Autolus Therapeutics by 2.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after buying an additional 11,197 shares during the last quarter. Finally, Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth $37,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.